GleamWall
中文EN

INBP INTEGRATED BIOPHARMA INC

Pharmaceutical Preparations · OTC · SEC CIK 1016504 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-23.1%
TTM net income YoY-644.0%
TTM EPS YoY-650.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin-0.8%
Operating margin-9.3%
Net margin-8.9%
FCF margin-3.8%
EBITDA margin-8.6%

Returns

ROE-19.5%
ROA-14.8%
ROIC (approx.)-20.4%
Asset turnover1.66x

Leverage & solvency

Liabilities / assets29.2%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$9.91M$9.80M$10.11M$11.28M$12.69M$14.18M$13.95M$12.61M
Cost of revenue$10.03M$9.77M$10.38M$11.25M$11.67M$12.71M$12.40M$11.44M
Gross profit-$112,000$28,000-$276,000$29,000$1.02M$1.47M$1.55M$1.17M
SG&A expense$849,000$897,000$809,000$943,000$856,000$880,000$812,000$969,000
Operating income-$961,000-$869,000-$1.08M-$914,000$163,000$589,000$739,000$202,000
Interest expense—$124,000-$39,000-$40,000-$33,000$76,000-$5,000-$11,000
Pretax income-$923,000-$850,000-$1.03M-$874,000$196,000$595,000$778,000$185,000
Income tax-$232,000$516,000-$198,000-$112,000$73,000$773,000$167,000$69,000
Net income-$691,000-$1.37M-$837,000-$762,000$123,000-$178,000$611,000$116,000
EBITDA-$894,000-$799,000-$1.02M-$836,000$240,000$660,000$815,000$285,000
EPS (basic)-0.02—-0.03-0.030.00—0.020.00
EPS (diluted)-0.02—-0.03-0.030.00—0.020.01
Weighted avg. shares (diluted)31.06M—31.06M31.06M31.42M—31.51M31.30M
Balance sheet
Cash & equivalents$3.12M$4.47M$5.83M$5.31M$4.73M$3.62M$2.96M$2.46M
Receivables$3.72M$3.33M$3.65M$3.59M$3.98M$5.43M$5.08M$4.23M
Inventory$8.54M$9.14M$8.12M$8.36M$10.47M$9.36M$10.08M$11.07M
Current assets$15.98M$17.38M$17.97M$17.82M$19.62M$18.76M$18.55M$18.15M
PP&E, net$1.81M$1.75M$1.70M$1.76M$1.82M$1.72M$1.81M$1.77M
Total assets$24.03M$25.34M$26.67M$23.55M$25.54M$24.90M$25.66M$25.66M
Current liabilities$5.45M$5.80M$5.53M$3.54M$4.76M$4.25M$4.98M$5.58M
Total liabilities$7.01M$7.67M$7.69M$3.78M$5.05M$4.58M$5.27M$5.93M
Shareholders' equity$17.02M$17.67M$18.98M$19.77M$20.49M$20.32M$20.38M$19,727
Shares outstanding31.09M31.06M31.09M31.09M31.06M31.06M30.30M30.30M
Cash flow statement
Operating cash flow-$1.22M-$1.19M$517,000$617,000$1.30M$591,000$616,000$201,000
Capital expenditure$124,000$149,000$0$24,000$173,000-$10,000$116,000$29,000
Free cash flow-$1.34M-$1.34M$517,000$593,000$1.13M$601,000$500,000$172,000
Investing cash flow-$124,000-$149,000$6,000-$24,000-$173,000-$4,000-$116,000-$29,000
Financing cash flow-$12,000-$12,000-$11,000-$11,000-$11,000$67,000$0$18,000
Depreciation & amortization$67,000$70,000$68,000$78,000$77,000$71,000$76,000$83,000
Stock-based compensation$39,000$51,000$50,000$42,000$49,000$44,000$45,000$43,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.